Lacour Brigitte, Goujon Stéphanie, Guissou Sandra, Guyot-Goubin Aurélie, Desmée Solène, Désandes Emmanuel, Clavel Jacqueline
aFrench National Registry of Childhood Solid Tumours, CHU, Nancy bFrench Registry of Childhood Haematopoietic Malignancies cINSERM, CESP Environmental Epidemiology of Cancer dUniversity Paris-Sud 11, Villejuif, France.
Eur J Cancer Prev. 2014 Sep;23(5):449-57. doi: 10.1097/CEJ.0000000000000006.
This paper reports the latest survival data for French childhood cancer patients at the national level. Data from the two French National Registries of Childhood Cancer (Haematopoietic Malignancies and Solid Tumours) were used to describe survival outcomes for 15,479 children diagnosed with cancer between 2000 and 2008 in mainland France. The overall survival was 91.7% at 1 year, 86.9% at 2 years and 81.6% at 5 years. Relative survival did not differ from overall survival even for infants. Survival was lower among infants for lymphoblastic leukaemia and astrocytoma, but higher for neuroblastoma. For all cancers considered together, 5-year survival increased from 79.5% in the first (2000-2002) diagnostic period to 83.2% in the last (2006-2008) period. The improvement was significant for leukaemia, both myeloid and lymphoid, central nervous system tumours (ependymoma) and neuroblastoma. The results remained valid in the multivariate analysis, and, for all cancers combined, the risk of death decreased by 20% between 2000-2002 and 2006-2008. The figures are consistent with various international estimates and are the result of progress in treatment regimens and collaborative clinical trials. The challenge for the French registries is now to study the long-term follow-up of survivors to estimate the incidence of long-term morbidities and adverse effects of treatments.
本文报告了法国儿童癌症患者在国家层面的最新生存数据。来自法国两个儿童癌症国家登记处（血液恶性肿瘤和实体瘤）的数据被用于描述2000年至2008年在法国大陆被诊断患有癌症的15479名儿童的生存结果。1年时的总生存率为91.7%，2年时为86.9%，5年时为81.6%。即使对于婴儿，相对生存率与总生存率也没有差异。婴儿中淋巴细胞白血病和星形细胞瘤的生存率较低，但神经母细胞瘤的生存率较高。对于所有考虑在内的癌症，5年生存率从第一个（2000 - 2002年）诊断期的79.5%升至最后一个（2006 - 2008年）诊断期的83.2%。白血病（髓系和淋巴细胞系）、中枢神经系统肿瘤（室管膜瘤）和神经母细胞瘤的改善显著。在多变量分析中结果仍然有效，并且对于所有合并的癌症，2000 - 2002年至2006 - 2008年期间死亡风险降低了20%。这些数据与各种国际估计一致，是治疗方案进展和协作临床试验的结果。法国登记处目前面临的挑战是研究幸存者的长期随访情况，以估计长期发病率和治疗不良反应的发生率。
